Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vera Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Vera Therapeutics, Inc.

VERA

Vera Therapeutics, Inc.

About Vera Therapeutics, Inc.

Vera Therapeutics is a late-stage biotech developing disease-modifying treatments for severe immunological diseases, primarily focusing on IgA nephropathy (IgAN). Its lead candidate, atacicept, targets B-cell pathways to reduce autoantibodies and immune complexes, aiming to slow kidney disease progression. The company also holds rights to novel therapies for BK virus infections and other autoimmune kidney conditions, leveraging expertise in immunology and biologic drug development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vera Therapeutics, Inc.

1
1
Vera Therapeutics, Inc. Vera Therapeutics Reports Increased Net Losses of $121M in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Vera Therapeutics, Inc. Vera Therapeutics Submits BLA for Atacicept, Reports Increased Operating Losses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Vera Therapeutics, Inc. Vera Therapeutics Reports $80.3 Million Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vera Therapeutics, Inc. Vera Therapeutics Reports $76.5 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vera Therapeutics, Inc. Vera Therapeutics Reports $51.7 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vera Therapeutics, Inc. Vera Therapeutics Reports $152.1 Million Net Loss for 2024, Increases in Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Vera Therapeutics, Inc. Vera Therapeutics Reports Significant Financial Developments, Increased Losses Amid Clinical Trial Spending

Via official filing (AI summary) | over 1 year ago | 0 comments